Ad hoc: MorphoSys Sues Janssen Biotech and Genmab for Patent Infringement
(Thomson Reuters ONE) -
MorphoSys AG /
Keyword(s): Legal proceeding /
Ad hoc: MorphoSys Sues Janssen Biotech and Genmab for Patent Infringement
. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today
announced that it filed a lawsuit in the United States (U.S.) District Court of
Delaware against Janssen Biotech, and Genmab, A/S for patent infringement of
U.S. Patent Number 8,263,746. This patent, which is owned by MorphoSys,
describes and claims antibodies with particular features that bind to CD38.
By its complaint, MorphoSys seeks redress for the infringing manufacture, use
and sale of Janssen's and Genmab's daratumumab, an antibody targeting CD38.
Janssen and Genmab recently obtained FDA approval on daratumumab and are
marketing the product as Darzalex® in the U.S. MorphoSys continues to develop
MOR202, its own investigational human antibody to CD38, for the treatment of
cancer, including multiple myeloma.
END OF AD HOC ANNOUNCEMENT
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 100 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®,
100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are
registered trademarks of the MorphoSys Group.
Darzalex® is a registered trademark of Johnson & Johnson.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies, The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties, Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated,
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors(at)morphosys.com
Ad hoc Release (PDF):
http://hugin.info/130295/R/2000355/737940.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via GlobeNewswire
[HUG#2000355]
Unternehmensinformation / Kurzprofil:
Datum: 04.04.2016 - 17:37 Uhr
Sprache: Deutsch
News-ID 461713
Anzahl Zeichen: 4040
contact information:
Town:
Martinsried / Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 226 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ad hoc: MorphoSys Sues Janssen Biotech and Genmab for Patent Infringement"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
